Life Science Investing Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin
Life Science Investing Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate
Life Science Investing Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences
Life Science Investing Mindset Pharma Selects Lead Clinical Candidates From "Family 2" of its Next Generation Psychedelic Drug Portfolio
Life Science Investing Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
Life Science Investing Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries
Life Science Investing Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds
Life Science Investing Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Life Science Investing Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders
Life Science Investing Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
Life Science Investing Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin
